Enveric Biosciences (ENVB) Cash & Equivalents (2010 - 2026)

Enveric Biosciences has reported Cash & Equivalents for 17 years, with the latest figure at $4.9 million in Q1 2026.

• Quarterly Cash & Equivalents rose 14.31% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 14.31% YoY) and the FY2025 annual result came in at $4.7 million, up 108.72% from the prior year.
• Cash & Equivalents advanced to $4.9 million in Q1 2026 per ENVB's latest filing, from $4.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $21.7 million in Q1 2022 and troughed at $2.2 million in Q4 2024.
• A 5-year average of $8.3 million and a median of $4.7 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 87.09% in 2023, then soared 108.72% in 2025.
• Over 5 years, Cash & Equivalents stood at $17.7 million in 2022, then plunged by 87.09% to $2.3 million in 2023, then fell by 2.05% to $2.2 million in 2024, then jumped by 108.72% to $4.7 million in 2025, then climbed by 4.94% to $4.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.9 million, $4.7 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.